Peripheral Artery Occlusive Disease (PAOD) is an indication for drug development with over 50 pipeline drugs currently active. According to GlobalData, preregistered drugs for Peripheral Artery Occlusive Disease (PAOD) have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Peripheral Artery Occlusive Disease (PAOD) compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Peripheral Artery Occlusive Disease (PAOD) overview

Peripheral artery occlusive disease (PAOD), also known as peripheral arterial disease (PAD), refers to a condition characterized by the narrowing or blockage of the arteries outside the heart, predominantly affecting the arteries in the legs. This narrowing occurs due to atherosclerosis, the buildup of plaque within the arterial walls, restricting blood flow to the limbs. Individuals with PAOD may experience symptoms primarily in the legs, such as intermittent claudication, which manifests as pain, cramping, or fatigue in the calf muscles during physical activity. The discomfort typically subsides with rest. In severe cases, decreased blood flow can cause pain even at rest, non-healing ulcers, and tissue damage, leading to gangrene. Several factors contribute to the development of peripheral artery occlusive disease, including smoking, diabetes, high blood pressure, high cholesterol levels, obesity, sedentary lifestyle, advanced age, and family history of cardiovascular disease.

For a complete picture of PTSR and LoA scores for drugs in Peripheral Artery Occlusive Disease (PAOD), buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.